Premium
Hypofractionated radiation therapy in unresectable stage iii non‐small cell lung cancer
Author(s) -
Slotman B. J.,
Njo K. H.,
De Jonge A.,
Meijer O. W. M.,
Karim A. B. M. F.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930915)72:6<1885::aid-cncr2820720616>3.0.co;2-7
Subject(s) - medicine , radiation therapy , lung cancer , stage (stratigraphy) , survival rate , nuclear medicine , dose fractionation , oncology , paleontology , biology
Background . Hypofractionation is the current choice for radiation therapy for patients with unresectable non‐small cell lung cancer (NSCLC) at the authors' institute. Methods . In this nonrandomized study, three hypofractionated radiation schedules (40‐Gy split course; 30–32 Gy in 6 fractions and 24 Gy in 3 fractions) are evaluated in 301 patients with unresectable Stage III NSCLC. Results . Patients with Stage IIIA disease treated with a 40‐Gy split course had longer survival ( P < 0.005) and a lower local relapse rate ( P < 0.01), but a higher distant failure rate ( P < 0.01) than those receiving 24–32 Gy. Survival for patients with Stage IIIA disease treated with 40 Gy at 1, 2, and 5 years was 47%, 22%, and 7%, respectively. For patients with Stage IIIB disease, the radiation scheme used did not correlate with survival and relapse rates. Survival at 1, 2, and 5 years was 30%, 9%, and 2%, respectively. The hypofractionated radiation schemes were well tolerated, and no severe complications were recorded. Conclusions . In patients with Stage IIIA disease, 40‐Gy split‐course radiation therapy yields survival rates comparable to those achieved with conventional radiation therapy. In patients with Stages IIIB and IV NSCLC, 24 Gy in 3 weekly fractions yields survival rates comparable to those achieved with higher total doses given in more fractions.